Optic Neuropathy, Ischemic clinical trials

The registry lists 55 studies for Optic Neuropathy, Ischemic across more than 10 countries. 11 are recruiting or about to start. 37 of them are mainly about Optic Neuropathy, Ischemic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.

Get an email when these change. Save the Optic Neuropathy, Ischemic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 26
Status unknown: 11
Recruiting: 8
Terminated: 5
Not yet recruiting: 3
Active, not recruiting: 1

Phase

Phase 2: 10
Phase 1: 7
Phase 4: 6
Phase 3: 6

Where

United States: 20
Canada: 5
Italy: 5
Iran, Islamic Republic of: 5
France: 4
Germany: 3

Who runs them

Shahid Beheshti University of Medical Sciences (5) · MD Stem Cells (2) · Regenera Pharma Ltd (2) · Quark Pharmaceuticals (2) · Rutgers, The State University of New Jersey (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · Fondazione G.B. Bietti, IRCCS (2) · National Eye Institute (NEI) (2)

What is being tested here

Drugs under test in Optic Neuropathy, Ischemic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Oxygen	1	0	1
Cenegermin	1	1	1
RPH201	0	0	2
QPI-1007	0	1	2
Bosentan	0	1	1
Platelet rich plasma	0	0	1
Cytidine Diphosphate Choline	0	0	1
Propofol	0	0	1
Desflurane	0	0	1
Ranibizumab	0	0	1

Coming up

2phase 3 studies under way

6studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

Feb 2027ENDOTHELION Study Group: Effect of Bosentan in NAION Patients · Phase 3 · University Hospital, Grenoble
Sep 2027Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) · Phase 3 · Dompé Farmaceutici S.p.A
Nov 2026NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study · Istanbul Saglik Bilimleri University
Dec 2026Effects of Different MAP Targets on Ocular Perfusion and Optic Nerve Microvasculature During Rhinoplasty · Hitit University
Jul 2027Stem Cell Ophthalmology Treatment Study II · MD Stem Cells
Oct 2027Optic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center Study · Barboni

Who these studies take

Of the 8 Optic Neuropathy, Ischemic studies recruiting now, 4 (50%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.

Recruiting studies that take each age, of 8
Age	Women	Men
10	0 (0%)	0 (0%)
18	5 (63%)	5 (63%)
30	5 (63%)	5 (63%)
40	5 (63%)	5 (63%)
50	8 (100%)	8 (100%)
65	8 (100%)	8 (100%)
75	8 (100%)	8 (100%)
85	6 (75%)	6 (75%)

Across all 55 studies, recruiting or not: 11% stop at 75 or younger and 7% at 65; 11% take children; 0% are for women only and 5% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 13, 2026.

Stopped1

Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.TerminatedOct 23, 2026NCT05353413

Studies

Recruiting first, then most recently updated. Showing 50 of 55. Browse all 55 → or search them.